期刊
SCIENTIFIC REPORTS
卷 7, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-03959-4
关键词
-
资金
- Fundacao para a Ciencia e a Tecnologia (FCT), Portugal [SFRH/BD/112201/2015]
- Marie Curie COFUND Programme NanoTRAINforGrowth, from the European Union's Seventh Framework Programme for research, technological development and demonstration [600375]
- Norte Portugal Regional Operational Programme (NORTE), under the PORTUGAL Partnership Agreement, through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000002]
- FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE - Operational Programme for Competitiveness and Internationalisation (POCI), Portugal
- Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]
- European Commission [H2020-644242-SAPHELY]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/112201/2015] Funding Source: FCT
Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobulin IgG1 used in antiangiogenic therapies due to its capacity to inhibit the interaction between vascular endothelial growth factor and its receptor. However, bevacizumab-based antiangiogenic therapy is not always effective due to poor treatment compliance associated to multiples administrations and drug resistance. In this work, we show a promising strategy of encapsulating bevacizumab to protect and deliver it, in a controlled manner, increasing the time between administrations and formulation shelflife. Nanoencapsulation of bevacizumab represents a significant advance for selective antiangiogenic therapies since extracellular, cell surface and intracellular targets can be reached. The present study shows that bevacizumab-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles does not impair its native-like structure after encapsulation and fully retain the bioactivity, making this nanosystem a new paradigm for the improvement of angiogenic therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据